Management of Hypoparathyroidism and Associated Disorders

Hypoparathyroidism is a rare endocrine disorder marked by deficient secretion of parathyroid hormone (PTH), leading to hypocalcaemia and hyperphosphataemia. Management aims to restore mineral homeostasis, prevent symptomatic hypocalcaemia and minimise long-term complications. Conventional therapy relies on oral calcium supplementation and active vitamin D analogues to maintain serum calcium in the low-normal range, yet this approach often results in fluctuating calcium levels, high pill burden and risk of renal calcifications and impaired renal function. Recombinant human PTH (rhPTH) replacement provides a physiological alternative, allowing reduced reliance on supplements and more stable biochemical control. Emerging therapies include extended-release PTH analogues and orally active PTH receptor agonists designed to mimic endogenous hormone dynamics while improving patient convenience. Beyond mineral management, comprehensive care addresses associated disorders such as nephrocalcinosis, bone fragility, neuropsychiatric challenges and cardiovascular risks. Regular monitoring of biochemical markers, imaging for renal and skeletal complications, and tailored patient education underpin an integrated, globally applicable strategy to optimise outcomes and enhance quality of life.

Research from Nature Portfolio

Recent studies have demonstrated the potential of orally active small molecules as full agonists at the parathyroid hormone type 1 receptor. One pioneering investigation showed that a novel compound administered orally to hypocalcaemic animal models rapidly restored serum calcium without inducing hypercalciuria, offering longer-lasting effects than injectable PTH. This approach may pave the way for non-invasive, patient-friendly treatments that more closely mimic the physiological action of endogenous hormone and reduce the burden of daily injections.

Management of Hypoparathyroidism and Associated Disorders publication trend

The graph below shows the total number of articles in management of hypoparathyroidism and associated disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Hypoparathyroidism: An endocrine disorder characterised by insufficient production of parathyroid hormone resulting in low serum calcium and high serum phosphate levels.

Parathyroid hormone (PTH): A peptide hormone secreted by parathyroid glands that regulates calcium and phosphate homeostasis in blood and bone.

Recombinant human PTH (rhPTH): A bioengineered form of full-length parathyroid hormone used as hormone replacement therapy to manage hypoparathyroidism.

Hypercalciuria: Excessive excretion of calcium in the urine, often a complication of calcium and vitamin D therapy.

Estimated glomerular filtration rate (eGFR): A measure of kidney function indicating the volume of fluid filtered by the glomeruli per minute.

Nephrocalcinosis: Deposition of calcium salts in renal parenchyma, which can impair kidney function over time.

References

1. Renal complications in chronic hypoparathyroidism – a systematic cross-sectional assessment. Frontiers in Endocrinology (2023).
2. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. European Journal of Endocrinology (2019).
3. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocrine Disorders (2013).
4. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism (2019).
5. Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nature Communications (2016).
6. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial. Journal of Bone and Mineral Research (2020).